EDIT · Editas Medicine, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.83M | - | $7.54M | $3.58M | $4.66M | - | $61.0K | $513.0K | $1.14M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $17.60M | - | $19.77M | $16.18M | $26.59M | - | $47.64M | $54.21M | $48.79M | - |
| SG&A | $10.23M | - | $12.32M | $12.86M | $13.38M | - | $18.09M | $18.21M | $19.34M | - |
| Total Operating Expenses | $27.83M | - | $32.09M | $55.12M | $80.82M | - | $65.73M | $72.42M | $68.13M | - |
| D&A | $483.0K | - | - | - | $1.92M | - | - | - | $1.41M | - |
| Operating Income | ($25.00M) | - | ($24.55M) | ($51.54M) | ($76.16M) | - | ($65.67M) | ($71.90M) | ($66.99M) | - |
| Interest Expense | $1.07M | - | $0 | $2.02M | $0 | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($24.98M) | - | ($25.12M) | ($53.23M) | ($76.09M) | - | ($62.14M) | ($67.61M) | ($61.95M) | - |
| EPS - Basic | ($0.26) | - | ($0.28) | ($0.63) | ($0.92) | - | ($0.75) | ($0.82) | ($0.76) | - |
| EPS - Diluted | ($0.26) | - | ($0.28) | ($0.63) | ($0.92) | - | ($0.75) | ($0.82) | ($0.76) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123.65M | $146.65M | $165.65M | $138.54M | $138.69M | $131.54M | $95.83M | $64.44M | $69.23M | $123.65M |
| Accounts Receivable | $2.59M | $15.18M | $8.13M | $588.0K | $510.0K | $16.27M | $126.0K | $244.0K | $245.0K | $10.19M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.33M | $2.60M | $3.16M | $6.72M | $5.46M | $5.49M | $12.49M | $13.77M | $7.97M | $8.27M |
| Current Assets | $128.07M | $163.90M | $176.89M | $182.80M | $224.84M | $289.31M | $271.14M | $286.35M | $305.56M | $340.83M |
| Total Assets | $149.34M | $186.53M | $201.75M | $210.58M | $263.65M | $341.59M | $327.57M | $384.80M | $440.35M | $499.15M |
| Current Liabilities | $39.78M | $46.25M | $61.77M | $65.94M | $73.11M | $77.22M | $72.35M | $74.31M | $66.49M | $63.22M |
| Long-term Debt | $47.18M | $53.60M | $54.07M | $51.67M | $49.58M | $52.43M | - | - | - | $0 |
| Total Liabilities | $144.93M | $159.25M | $188.30M | $191.39M | $201.23M | $207.31M | $151.93M | $152.79M | $145.95M | $150.06M |
| Stockholders' Equity | $4.41M | $27.29M | $13.45M | $19.19M | $62.42M | $134.27M | $175.63M | $232.01M | $294.40M | $349.10M |
| Retained Earnings | ($1.65B) | ($1.63B) | ($1.62B) | ($1.60B) | ($1.54B) | ($1.47B) | ($1.42B) | ($1.36B) | ($1.29B) | ($1.23B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($23.06M) | - | - | - | ($47.80M) | - | - | - | ($49.87M) | - |
| Investing Cash Flow | $64.0K | - | - | - | $56.39M | - | - | - | ($4.75M) | - |
| Financing Cash Flow | $0 | - | - | - | ($1.44M) | - | - | - | $192.0K | - |
| CapEx | $92.0K | - | - | - | $114.0K | - | - | - | $1.87M | - |
| Free Cash Flow | ($23.15M) | - | - | - | ($47.91M) | - | - | - | ($51.74M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -883.2% | - | -325.4% | -1440.6% | -1635.1% | - | -107649.2% | -14016.2% | -5902.3% | - |
| EBITDA margin | -866.1% | - | - | - | -1593.9% | - | - | - | -5778.1% | - |
| Net margin | -882.4% | - | -333.0% | -1487.8% | -1633.5% | - | -101870.5% | -13178.8% | -5458.1% | - |
| Free cash flow margin | -817.8% | - | - | - | -1028.6% | - | - | - | -4558.9% | - |
| FCF / Net income | 0.93 | - | - | - | 0.63 | - | - | - | 0.84 | - |
| R&D / Revenue | 621.7% | - | 262.2% | 452.2% | 570.9% | - | 78096.7% | 10567.3% | 4298.4% | - |
| SG&A / Revenue | 361.5% | - | 163.3% | 359.4% | 287.1% | - | 29652.5% | 3548.9% | 1703.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -16.7% | - | -12.4% | -25.3% | -28.9% | - | -19.0% | -17.6% | -14.1% | - |
| Return on equity | -566.7% | - | -186.7% | -277.4% | -121.9% | - | -35.4% | -29.1% | -21.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.22 | 3.54 | 2.86 | 2.77 | 3.08 | 3.75 | 3.75 | 3.85 | 4.60 | 5.39 |
| Quick ratio | 3.22 | 3.54 | 2.86 | 2.77 | 3.08 | 3.75 | 3.75 | 3.85 | 4.60 | 5.39 |
| Cash ratio | 3.11 | 3.17 | 2.68 | 2.10 | 1.90 | 1.70 | 1.32 | 0.87 | 1.04 | 1.96 |
| Leverage | ||||||||||
| Debt / Equity | 10.70 | 1.96 | 4.02 | 2.69 | 0.79 | 0.39 | - | - | - | 0.00 |
| Debt / Assets | 0.32 | 0.29 | 0.27 | 0.25 | 0.19 | 0.15 | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -23.3x | - | - | -25.5x | - | - | - | - | - | - |
| Equity multiplier | 33.88 | 6.84 | 15.00 | 10.97 | 4.22 | 2.54 | 1.87 | 1.66 | 1.50 | 1.43 |
| Liabilities / Assets | 0.97 | 0.85 | 0.93 | 0.91 | 0.76 | 0.61 | 0.46 | 0.40 | 0.33 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.04 | 0.02 | 0.02 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 334d | - | 393d | 60d | 40d | - | 754d | 174d | 79d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 54.8x | - | 23.2x | 9.7x | 1.5x | - | 1.6x | 1.7x | 2.1x | - |
| P / S | 85.4x | - | 41.4x | 51.9x | 20.7x | - | 4611.1x | 749.3x | 535.7x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -39.2% | - | 12265.6% | 597.5% | 310.4% | - | -98.9% | -82.2% | -88.5% | - |
| Revenue CAGR (3y) | -34.0% | - | 464.2% | -17.5% | -11.7% | - | -78.6% | 10.6% | -44.1% | - |
| Revenue CAGR (5y) | -15.3% | - | -34.6% | -19.7% | -4.0% | - | -56.3% | -26.1% | -11.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 67.2% | - | 62.6% | 28.3% | -13.7% | - | -30.9% | -63.1% | -31.5% | - |
| Net income growth (YoY) | 67.2% | - | 59.6% | 21.3% | -22.8% | - | -38.0% | -67.8% | -26.3% | - |
| EPS growth (YoY) | 71.7% | - | 62.7% | 23.2% | -21.1% | - | -36.4% | -46.4% | -7.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 51.7% | - | - | - | 7.4% | - | - | - | -37.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -92.9% | -79.7% | -92.3% | -91.7% | -78.8% | -61.5% | -51.3% | -42.0% | -7.3% | -3.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$40.52M totalReportable Segment$40.52M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Editas Medicine against the 5 most active filers in the same SIC group.